{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:06:55Z","timestamp":1789657615074,"version":"4.0.1"},"reference-count":25,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,8,19]]},"DOI":"10.2967\/jnumed.126.272687","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:40:20Z","timestamp":1789656020000},"page":"jnumed.126.272687","source":"Crossref","is-referenced-by-count":0,"title":["From Bench to Bedside: A Critical Appraisal of Somatostatin Receptor Antagonists in the Theranostic Management of Neuroendocrine Neoplasms"],"prefix":"10.2967","author":[{"given":"Esmail","family":"Jafari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik E.","family":"Juweid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Raeisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atena","family":"Najdian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Javad","family":"Rekabpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Assadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"2026091707401092000_jnumed.126.272687v1.1","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1053\/j.semnuclmed.2025.04.003","article-title":"Targets for molecular imaging of neuroendocrine tumors (NETs): an overview and update","volume":"55","author":"Jafari","year":"2025","journal-title":"Semin Nucl Med."},{"key":"2026091707401092000_jnumed.126.272687v1.2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0607761103"},{"key":"2026091707401092000_jnumed.126.272687v1.3","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1007\/s00259-024-06639-4","article-title":"Gallium-68 labeled somatostatin receptor antagonist PET\/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China","volume":"51","author":"Liu","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091707401092000_jnumed.126.272687v1.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264890"},{"key":"2026091707401092000_jnumed.126.272687v1.5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1026"},{"key":"2026091707401092000_jnumed.126.272687v1.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.102764"},{"key":"2026091707401092000_jnumed.126.272687v1.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.087999"},{"key":"2026091707401092000_jnumed.126.272687v1.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.177733"},{"key":"2026091707401092000_jnumed.126.272687v1.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.235093"},{"key":"2026091707401092000_jnumed.126.272687v1.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05564-0"},{"key":"2026091707401092000_jnumed.126.272687v1.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.199760"},{"key":"2026091707401092000_jnumed.126.272687v1.12","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00259-021-05512-y","article-title":"A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE","volume":"49","author":"Zhu","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091707401092000_jnumed.126.272687v1.13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3390\/ph17030275","article-title":"Head-to-head comparison of SSTR antagonist [68Ga]Ga-DATA5m-LM4 with SSTR agonist [68Ga]Ga-DOTANOC PET\/CT in patients with well differentiated gastroenteropancreatic neuroendocrine tumors: a prospective imaging study","volume":"17","author":"Viswanathan","year":"2024","journal-title":"Pharmaceuticals (Basel)."},{"key":"2026091707401092000_jnumed.126.272687v1.14","doi-asserted-by":"crossref","first-page":"14590","DOI":"10.3390\/ijms232314590","article-title":"[68Ga]Ga-DATA5m-LM4, a PET radiotracer in the diagnosis of SST2R-positive tumors: preclinical and first clinical results","volume":"23","author":"Kanellopoulos","year":"2022","journal-title":"Int J Mol Sci."},{"key":"2026091707401092000_jnumed.126.272687v1.15","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1007\/s00259-024-06790-y","article-title":"Evaluation of the safety, biodistribution, dosimetry of [18F]AlF-NOTA-LM3 and head-to-head comparison with [68Ga]Ga-DOTATATE in patients with well-differentiated neuroendocrine tumors: an interim analysis of a prospective trial","volume":"51","author":"Liu","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091707401092000_jnumed.126.272687v1.16","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1007\/s00259-021-05249-8","article-title":"Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga] Ga-DOTA-TATE","volume":"48","author":"Xie","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091707401092000_jnumed.126.272687v1.17","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00259-024-06978-2","article-title":"Synthesis and preclinical evaluation of [18F]AlF-NOTA-Asp2-PEG2-JR11 as a novel antagonist radioligand for PET imaging of somatostatin receptor","volume":"52","author":"Liang","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091707401092000_jnumed.126.272687v1.18","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1038\/s41598-025-85143-7","article-title":"PET imaging of 52Mn labeled DOTATATE and DOTAJR11","volume":"15","author":"Omweri","year":"2025","journal-title":"Sci Rep."},{"key":"2026091707401092000_jnumed.126.272687v1.19","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.3390\/cancers17183070","article-title":"Peptide receptor radionuclide therapy (PRRT) using actinium-225- and Ac-225\/Lutetium-177-labeled (TANDEM) somatostatin receptor antagonist DOTA-LM3 in patients with neuroendocrine neoplasm: a retrospective study concerning safety and survival","volume":"17","author":"Perrone","year":"2025","journal-title":"Cancers (Basel)."},{"key":"2026091707401092000_jnumed.126.272687v1.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.258889"},{"key":"2026091707401092000_jnumed.126.272687v1.21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00259-023-06383-1","article-title":"A phase I\/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours","volume":"51","author":"Wild","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091707401092000_jnumed.126.272687v1.22","doi-asserted-by":"crossref","unstructured":"Brosch-Lenz JF Dreher N B\u00e4\u00dfler J . SSTR-directed radiopharmaceutical therapy in a patient with small cell lung cancer: an intrapatient comparison of SSTR agonist and antagonist. EANM Innovation. 2026:100024.","DOI":"10.1016\/j.eanmi.2026.100024"},{"key":"2026091707401092000_jnumed.126.272687v1.23","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1007\/s00259-024-06641-w","article-title":"First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum","volume":"51","author":"Fricke","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091707401092000_jnumed.126.272687v1.24","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00259-024-07035-8","article-title":"Preclinical investigation of [149Tb]Tb-DOTATATE and [149Tb]Tb-DOTA-LM3 for tumor-targeted alpha therapy","volume":"52","author":"Mapanao","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091707401092000_jnumed.126.272687v1.25","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.7150\/thno.113354","article-title":"Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells","volume":"15","author":"Nguyen","year":"2025","journal-title":"Theranostics."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.126.272687","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:40:33Z","timestamp":1789656033000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.126.272687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":25,"alternative-id":["10.2967\/jnumed.126.272687"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.126.272687","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}